Login Register Cart 0
Generic placeholder image

Pharmaceutical Nanotechnology

Editor-in-Chief

ISSN (Print): 2211-7385
ISSN (Online): 2211-7393

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Development of Fluorescently Labeled Self-Emulsifying Drug Delivery Systems (SEDDS) for Prolonged Stability, In Vitro Sustained Release, and Cellular Uptake

Author(s): Ahmad Saleh Malkawi*, Razan Haddad, Azhar Malkawi and Nasr Alrabadi

Volume 10, Issue 2, 2022

Published on: 12 May, 2022

Page: [146 - 161] Pages: 16

DOI: 10.2174/2211738510666220314103400

Price: $65

Abstract

Aims: In this study, four fluorescein hydrophobic ionic complexes were formed with the cationic polymers Eudragit RS, Eudragit RL, Eudragit E, and polyethyleneimine (PEI) to provide fluorescein sustained release, sustained cellular uptake, and stability.

Methods: Complexes were loaded in a self-emulsifying drug delivery system (SEDDS) composed of 40% Tween 80, 20% Kolliphor EL, 15% 2-n-Octyl-1-dodecanol, and 25% dipropylene glycol. SEDDS were investigated regarding their size, polydispersity index (PDI), zeta potential, and cytotoxicity. Fluorescein release from SEDDS was performed in phosphate buffer (pH 6.8 and pH 8), and the released fluorescein was evaluated for cellular uptake. Moreover, fluorescein from all of the SEDDS pre-concentrates was released at different time points to check its long-term stability over six months.

Results: The average fluorescein load in SEDDS was 0.045%. SEDDS showed an average droplet size of 24.9 ± 1.6 nm with PDI ≤ 0.3. SEDDS complexes diluted 1:100 increased the zeta potential from -7.3 mV to +3.7 mV and provided > 85% cell viability. A 92.27 ± 3.18% fluorescein exhibited a few seconds of immediate release when used as control or PEI complex in SEDDS. On the contrary, Eudragit-fluorescein complexes in SEDDS showed sustained release of 87.01 ± 5.22% fluorescein in ≤ 70 min with 22.19 ± 14.56% and 59.27 ± 16.57% released at 10 min in pH 6.8 and pH 8 release media, respectively. Comparatively, the medium at pH 6.8 maintained a significantly improved sustained fluorescein release (p ≤ 0.001). Furthermore, Eudragit RS/RL compared to Eudragit E, significantly exhibited a slower fluorescein release rate from SEDDS (p ≤ 0.01). The cellular uptake of the released fluorescein was 72.4 ± 8.2% for all SEDDS complexes after 3 h. Eudragit complexes compared to PEI complex in SEDDS significantly showed m ore sustained fluorescein cellular uptake at 1 h and 2 h (p ≤ 0.001). However, SEDDS complexes showed the longest fluorescein stability with PEI after six months, whereas fluorescein stability for SEDDS containing fluorescein as Eudragit complex and control showed 39.1% and 82.5% fluorescence decrease, respectively, after three months.

Conclusion: In the developed SEDDS, the presence of hydrophobic ionic complexes can significantly promote longer stability and sustained cellular uptake of fluorescein while releasing in a sustained manner.

Keywords: Hydrophobic ion pairing, dielectric constant, SEDDS, nanoemulsions, sustained release, fluorescein.

« Previous Next »
Graphical Abstract

[1]
Singh AV, Romeo A, Scott K, et al. Emerging technologies for in vitro inhalation toxicology. Adv Healthc Mater 2021; 10(18), e2100633.
[http://dx.doi.org/10.1002/adhm.202100633] [PMID: 34292676]
[2]
Singh AV, Maharjan RS, Kromer C, et al. Advances in smoking related in vitro inhalation toxicology: A perspective case of challenges and opportunities from progresses in lung-on-chip technologies. Chem Res Toxicol 2021; 34(9): 1984-2002.
[http://dx.doi.org/10.1021/acs.chemrestox.1c00219] [PMID: 34397218]
[3]
Singh AV, Chandrasekar V, Janapareddy P, et al. Emerging application of nanorobotics and artificial intelligence to cross the BBB: Ad-vances in design, controlled maneuvering, and targeting of the barriers. ACS Chem Neurosci 2021; 12(11): 1835-53.
[http://dx.doi.org/10.1021/acschemneuro.1c00087] [PMID: 34008957]
[4]
Xu W, Ling P, Zhang T. Polymeric micelles, a promising drug delivery system to enhance bioavailability of poorly water-soluble drugs. J Drug Deliv 2013; 2013, 340315.
[http://dx.doi.org/10.1155/2013/340315] [PMID: 23936656]
[5]
Liu L, Yao W, Rao Y, Lu X, Gao J. pH-Responsive carriers for oral drug delivery: Challenges and opportunities of current platforms. Drug Deliv 2017; 24(1): 569-81.
[http://dx.doi.org/10.1080/10717544.2017.1279238] [PMID: 28195032]
[6]
Hauptstein S, Prüfert F, Bernkop-Schnürch A. Self-nanoemulsifying drug delivery systems as novel approach for pDNA drug delivery. Int J Pharm 2015; 487(1-2): 25-31.
[http://dx.doi.org/10.1016/j.ijpharm.2015.03.064] [PMID: 25839413]
[7]
Forbes DC, Peppas NA. Oral delivery of small RNA and DNA. J Control Release 2012; 162(2): 438-45.
[http://dx.doi.org/10.1016/j.jconrel.2012.06.037] [PMID: 22771979]
[8]
Mohsin K, Alamri R, Ahmad A, Raish M, Alanazi FK, Hussain MD. Development of self-nanoemulsifying drug delivery systems for the enhancement of solubility and oral bioavailability of fenofibrate, a poorly water-soluble drug. Int J Nanomedicine 2016; 11: 2829-38.
[PMID: 27366063]
[9]
Griesser J, Hetényi G, Kadas H, Demarne F, Jannin V, Bernkop-Schnürch A. Self-emulsifying peptide drug delivery systems: How to make them highly mucus permeating. Int J Pharm 2018; 538(1-2): 159-66.
[http://dx.doi.org/10.1016/j.ijpharm.2018.01.018] [PMID: 29339247]
[10]
Liu M, Wu L, Zhu X, et al. Core-shell stability of nanoparticles plays an important role for overcoming the intestinal mucus and epitheli-um barrier. J Mater Chem B Mater Biol Med 2016; 4(35): 5831-41.
[http://dx.doi.org/10.1039/C6TB01199C] [PMID: 32263756]
[11]
Karamanidou T, Bourganis V, Kammona O, Kiparissides C. Lipid-based nanocarriers for the oral administration of biopharmaceutics. Nanomedicine (Lond) 2016; 11(22): 3009-32.
[http://dx.doi.org/10.2217/nnm-2016-0265] [PMID: 27781558]
[12]
Karamanidou T, Karidi K, Bourganis V, Kontonikola K, Kammona O, Kiparissides C. Effective incorporation of insulin in mucus perme-ating self-nanoemulsifying drug delivery systems . Eur J Pharm Biopharm 2015; 97(Pt A): 223-9..
[http://dx.doi.org/10.1016/j.ejpb.2015.04.013] [PMID: 25933940]
[13]
Washington C, Evans K. Release rate measurements of model hydrophobic solutes from submicron triglyceride emulsions. J Control Release 1995; 33: 383-90.
[http://dx.doi.org/10.1016/0168-3659(94)00110-G]
[14]
Trotta M. Influence of phase transformation on indomethacin release from microemulsions. J Control Release 1999; 60(2-3): 399-405.
[http://dx.doi.org/10.1016/S0168-3659(99)00094-2] [PMID: 10425344]
[15]
Bernkop-Schnürch A, Jalil A. Do drug release studies from SEDDS make any sense? J Control Release 2018; 271: 55-9.
[http://dx.doi.org/10.1016/j.jconrel.2017.12.027] [PMID: 29287908]
[16]
Malkawi A, Jalil A, Nazir I, Matuszczak B, Kennedy R, Bernkop-Schnürch A. Self-emulsifying drug delivery systems: Hydrophobic drug polymer complexes provide a sustained release in vitro. Mol Pharm 2020; 17(10): 3709-19.
[http://dx.doi.org/10.1021/acs.molpharmaceut.0c00389] [PMID: 32841038]
[17]
National library of medicine Available from. https://pubchem.ncbi.nlm.nih.gov/compound/Fluorescein-disodium-salt
[18]
Panchompoo J, Aldous L, Baker M, Wallace MI, Compton RG. One-step synthesis of fluorescein modified nano-carbon for Pd(II) detec-tion via fluorescence quenching. Analyst (Lond) 2012; 137(9): 2054-62.
[http://dx.doi.org/10.1039/c2an16261j] [PMID: 22421892]
[19]
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46(1-3): 3-26.
[http://dx.doi.org/10.1016/S0169-409X(00)00129-0] [PMID: 11259830]
[20]
Pinsuwan S, Li A, Yalkowsky S H. Correlation of octanol/water solubility ratios and partition coefficients. J Chem Eng Data 1995; 40(): 623-6..
[http://dx.doi.org/10.1021/je00019a019]
[21]
Akkus ZB, Nazir I, Jalil A, Tribus M, Bernkop-Schnürch A. Zeta potential changing polyphosphate nanoparticles: A promising approach to overcome the mucus and epithelial barrier. Mol Pharm 2019; 16(6): 2817-25.
[http://dx.doi.org/10.1021/acs.molpharmaceut.9b00355] [PMID: 31070926]
[22]
Nazir I, Fürst A, Lupo N, Hupfauf A, Gust R, Bernkop-Schnürch A. Zeta potential changing self-emulsifying drug delivery systems: A promising strategy to sequentially overcome mucus and epithelial barrier. Eur J Pharm Biopharm 2019; 144: 40-9.
[http://dx.doi.org/10.1016/j.ejpb.2019.09.007] [PMID: 31505225]
[23]
Singh AV, Maharjan RS, Jungnickel H, et al. Evaluating particle emissions and toxicity of 3D pen printed filaments with metal nanoparticles as additives: In vitro and in silico discriminant function analysis ACS Sustainable Chem Eng. 2021; 9: pp. (35)11724-37..
[http://dx.doi.org/10.1021/acssuschemeng.1c02589]
[24]
Hudson RA, Scott RM, Vinogradov SN. Hydrogen-bonded complex-ion-pair equilibriums in 3,4-dinitrophenol-amine-aprotic solvent systems. J Phys Chem 1972; 76: 1989-93.
[http://dx.doi.org/10.1021/j100658a013]
[25]
Crooks JH, Robinson BH. Hydrogen-bonded and ion-pair complexes in aprotic solvents. Faraday Symp Chem Soc 1975; 10: 29-40.
[http://dx.doi.org/10.1039/fs9751000029]
[26]
Jones JW, Gibson HW. Ion pairing and host−guest complexation in low dielectric constant solvents. J Am Chem Soc 2003; 125(23): 7001-4.
[http://dx.doi.org/10.1021/ja034442x]
[27]
Van EV, Haulait-Pirson MC. Influence of the dielectric constant on ion-pair and ion-ligand complex formation. J Solution Chem 1977; 6(11): 757-70.
[http://dx.doi.org/10.1007/BF00650452]
[28]
Kunin R, Winger AG. Liquid ion-exchange technology. Angew Chem Int Ed Engl 1962; 1(3): 149-55.
[http://dx.doi.org/10.1002/anie.196201491]
[29]
Jin J-Y, Kim H-G, Hong C-H, Suh E-K, Lee Y-S. White light emission from a blue LED, combined with a sodium salt of fluorescein dye. In: Synth Met 2007; 157: pp. 138-141.
[30]
Thompson WE, Warren RJ, Eisdorfer IB, Zarembo JE. Identification of primary, secondary, and tertiary pharmaceutical amines by the infrared spectra of their salts. J Pharm Sci 1965; 54(12): 1819-21.
[http://dx.doi.org/10.1002/jps.2600541231]
[31]
Griesser J, Hetényi G, Moser M, Demarne F, Jannin V, Bernkop-Schnürch A. Hydrophobic ion pairing: Key to highly payloaded self-emulsifying peptide drug delivery systems. 2017; 520: (1- 2):267-274..
[32]
Suchaoin W. Pereira de Sousa, Netsomboon K, Lam HT, Laffleur F, Bernkop-Schnürch A. Development and in vitro evaluation of zeta potential changing self-emulsifying drug delivery systems for enhanced mucus permeation. Int J Pharm 2016; 510(1): 255-62.
[http://dx.doi.org/10.1016/j.ijpharm.2016.06.045] [PMID: 27329673]
[33]
Nazir I, Leichner C, Le-Vinh B, Bernkop-Schnürch A. Surface phosphorylation of nanoparticles by hexokinase: A powerful tool for cellu-lar uptake improvement. J Colloid Interface Sci 2018; 516: 384-91.
[http://dx.doi.org/10.1016/j.jcis.2018.01.082] [PMID: 29408127]
[34]
Jelkmann M, Leichner C, Menzel C, Kreb V, Bernkop-Schnürch A. Cationic starch derivatives as mucoadhesive and soluble excipients in drug delivery. Int J Pharm 2019; 570, 118664.
[http://dx.doi.org/10.1016/j.ijpharm.2019.118664]
[35]
Lungwitz U, Breunig M, Blunk T, Göpferich A. Polyethylenimine-based non-viral gene delivery systems. Eur J Pharm Biopharm 2005; 60(2): 247-66.
[http://dx.doi.org/10.1016/j.ejpb.2004.11.011] [PMID: 15939236]
[36]
Hao F, Li Y, Zhu J, et al. Polyethylenimine-based formulations for delivery of oligonucleotides. Curr Med Chem 2019; 26(13): 2264-84.
[http://dx.doi.org/10.2174/0929867325666181031094759] [PMID: 30378483]
[37]
Zhang W, Li X, Ye T, et al. Nanostructured lipid carrier surface modified with Eudragit RS 100 and its potential ophthalmic functions. Int J Nanomedicine 2014; 9: 4305-15.
[PMID: 25246787]
[38]
Nazir I, Asim MH. Dizdarević A, Bernkop-Schnürch A. Self-emulsifying drug delivery systems: Impact of stability of hydrophobic ion pairs on drug release. Int J Pharm 2019; 561: 197-205.
[http://dx.doi.org/10.1016/j.ijpharm.2019.03.001] [PMID: 30836151]
[39]
Doughty MJ. pH dependent spectral properties of sodium fluorescein ophthalmic solutions revisited. Ophthalmic Physiol Opt 2010; 30(2): 167-74.
[http://dx.doi.org/10.1111/j.1475-1313.2009.00703.x] [PMID: 20444121]
[40]
Barry RE, Behrendt WA. Studies on the pharmacokinetics of fluorescein and its dilaurate ester under the conditions of the fluorescein dilaurate test. Arzneimittelforschung 1985; 35(3): 644-8.
[PMID: 4039592]
[41]
Salimi E, Le-Vinh B, Zahir-Jouzdani F, Matuszczak B, Ghaee A, Bernkop-Schnürch A. Self-emulsifying drug delivery systems changing their zeta potential via a flip-flop mechanism. Int J Pharm 2018; 550(1-2): 200-6.
[http://dx.doi.org/10.1016/j.ijpharm.2018.08.046] [PMID: 30149127]
[42]
McCartney F, Jannin V, Chevrier S, et al. Labrasol® is an efficacious intestinal permeation enhancer across rat intestine: Ex vivo and in vivo rat studies. J Control Release 2019; 310: 115-26.
[http://dx.doi.org/10.1016/j.jconrel.2019.08.008] [PMID: 31401199]
[43]
Nazir I, Shahzadi I, Jalil A, Bernkop-Schnürch A. Hydrophobic H-bond pairing: A novel approach to improve membrane permeability. Int J Pharm 2020; 573, 118863.
[http://dx.doi.org/10.1016/j.ijpharm.2019.118863] [PMID: 31765777]
[44]
Alvi MM, Chatterjee P. A prospective analysis of co-processed non-ionic surfactants in enhancing permeability of a model hydrophilic drug. AAPS PharmSciTech 2014; 15(2): 339-53.
[http://dx.doi.org/10.1208/s12249-013-0065-8] [PMID: 24357111]
[45]
Smith S, Pretorius W. The conservative behavior of fluorescein. Water SA 2002; 28(4): 403-539.
[http://dx.doi.org/10.4314/wsa.v28i4.4913]

Rights & Permissions Print Cite
Article Metrics
23
2
© 2024 Bentham Science Publishers | Privacy Policy